Mechanisms of Post-Bariatric Hypoglycemia

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    Joslin Diabetes Center
Updated on 19 February 2024
diabetes
hypoglycemia
hormone levels
glucagon
continuous glucose monitoring
acarbose
hypoglycaemic
dietary intervention
gastrointestinal surgery
tolerance test
antihyperglycemic
neuroglycopenia
sensitivity testing

Summary

Post-bariatric hypoglycemia (PBH) is an increasingly recognized syndrome that is incompletely understood.

The purpose of this study is to increase our level of understanding by investigating mechanisms contributing to this condition.

Participation in this study will take place over four visits, which will include the

following
  • Wearing of a continuous glucose monitoring device;
  • Providing a stool sample (collected at home);
  • Measuring glucose and hormone levels in response to a meal;
  • Measuring glucose and hormone levels in response to an injection of glucagon;
  • Measuring hormone levels while we gradually lower glucose levels, and during a controlled period of a low glucose level (hypoglycemic clamp).

We will test the hypothesis that counterregulatory hormone responses are impaired in individuals with PBH, and that differences in the intestinal bacteria (microbiome) may contribute to this condition.

Description

Bariatric surgery is increasingly recognized as a potent tool for the treatment of type 2 diabetes (T2D), yielding not only weight loss but also rapid improvements in glycemia allowing discontinuation of diabetes-related medication within days after surgery. However, along with this metabolic success comes an increased incidence of severe hypoglycemia (termed post-bariatric hypoglycemia; PBH) for a subset of individuals.

The goal of these studies is to identify physiological and molecular mechanisms that underlie PBH, to determine whether these changes also contribute to surgery-induced improvements in glucose regulation (homeostasis), and to define potential new therapeutic interventions for PBH.

Participation in this study will take place over four visits, which will include the

following
  • Detailed history, physical exam, and laboratory testing to determine study eligibility
  • Assessment of glucose patterns using a masked continuous glucose monitor;
  • Analysis of a stool sample (collected at home);
  • Measuring glucose and hormone levels in response to a meal;
  • Measuring glucose and hormone levels in response to an injection of glucagon;
  • Measuring hormone levels while we gradually lower glucose levels, and during a controlled period of a low glucose level (hypoglycemic clamp).

We will test the hypothesis that counterregulatory hormone responses are impaired in individuals with PBH, and that differences in the intestinal bacteria (microbiome) and hormones produced in response to a meal may contribute to this condition.

Details
Condition Hypoglycemia, Hypocalcemia
Age 18years - 70years
Treatment Activity Monitor, Continuous Glucose Monitoring, Mixed meal tolerance test, Glucagon Sensitivity Testing, Hypoglycemic Hyperinsulinemic Clamp, analysis of fecal microbiome
Clinical Study IdentifierNCT04428866
SponsorJoslin Diabetes Center
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

For PBH group only: Males or females diagnosed with ongoing post-bariatric hypoglycemia with prior episodes of neuroglycopenia, unresponsive to dietary intervention (low glycemic index, controlled carbohydrate portions) and trial of acarbose therapy at the maximally tolerated dose
For post-RYGB group without PBH: Males or females with history of RYGB and no history of symptomatic hypoglycemia
For non-surgical controls only: Males or females with no history of upper gastrointestinal surgery and no history of hypoglycemia or diabetes
Age 18-70 years of age, inclusive, at screening
Willingness to provide informed consent and follow all study procedures, including attending all scheduled visits

Exclusion Criteria

Documented hypoglycemia occurring in the fasting state (> 12 hours fast)
Chronic kidney disease stage 4 or 5 (including end-stage renal disease)
Hepatic disease, including serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin < 3.0 g/dL; or serum bilirubin > 2.0
Congestive heart failure, New York Heart Association class II, III or IV
History of myocardial infarction, unstable angina or revascularization within the past 6 months or 2 or more risk factors for coronary artery disease including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use
History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia
Concurrent administration of -blocker therapy
History of a cerebrovascular accident
Seizure disorder (other than with suspect or documented hypoglycemia)
Active treatment with any diabetes medications except for acarbose
Active malignancy, except basal cell or squamous cell skin cancers
Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)
Known insulinoma
Major surgical operation within 30 days prior to screening
Hematocrit < 33% (women) or <36% (men)
Bleeding disorder, treatment with warfarin, or platelet count <50,000
Blood donation (1 pint of whole blood) within the past 2 months
Active alcohol abuse or substance abuse
Current administration of oral or parenteral corticosteroids
Pregnancy and/ or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an intrauterine device, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence
Use of an investigational drug within 30 days prior to screening
There will be no involvement of special vulnerable populations such as
fetuses, neonates, pregnant women, children, prisoners, institutionalized or
incarcerated individuals, or others who may be considered vulnerable
populations
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.